Bristol-Myers says drug slows joint damage in RA
Key points
- Bristol-Myers Squibb Co. said on Thursday that a late-stage trial showed its experimental Rheumatoid Arthritis drug abatacept slowed the progression of joint damage in patients with the disease.
- The results come from additional analysis of phase III trial data that were released last October showing the drug met the main goal of the trial, which was to improve the signs and symptoms of the disease in patients who had failed certain other therapies.
- The latest results, which showed a significant inhibition of joint damage, were presented at a conference in Europe.
- Abatacept could be the first in a new class of drugs known as T-cell co-stimulation modulators, which slow the body's response to inflammation.
Bristol-Myers Squibb Co. said on Thursday that a late-stage trial showed its experimental Rheumatoid Arthritis drug abatacept slowed the progression of joint damage in patients with the disease.
The results come from additional analysis of phase III trial data that were released last October showing the drug met the main goal of the trial, which was to improve the signs and symptoms of the disease in patients who had failed certain other therapies.
The latest results, which showed a significant inhibition of joint damage, were presented at a conference in Europe. If approved, analysts expect the drug to generate sales of $500 million to more than $1 billion.
Abatacept could be the first in a new class of drugs known as T-cell co-stimulation modulators, which slow the body's response to inflammation.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Bones, Joints & Pain →Male smokers less likely to need joint replacement surgery of hip or knee
Surprising results from a new study revealed that men who smoke had less risk of undergoing total joint replacement surgery than those who never smoked. Researchers also reported that men who were overweight, or who…
9 July 2011
